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Integrin-Linked Kinase Inhibitor KP-392 Demonstrates
Clinical Benefitsin an Orthotopic Human Non-small Cell
Lung Cancer Model
Jiang Liu, MD,* Penny C. Costello, PhD,† Nhu-An Pham, MSc,‡ Melania Pintillie, MSc,§
Mogjan Jabali, PhD, Jasbinder Sanghera, PhD,¶ Ming-Sound Tsao, MD,‡#**
and Michael R. Johnston, MD*
Introduction: The overexpression of integrin-linked kinase (ILK)
has been implicated in the promotion of tumor invasion and metas-
tasis. We studied the anticancer effects of KP-392, a potent selective
inhibitor of ILK in the NCI-H460 cell line. In vitro, KP-392
inhibited ILK activity of H460 cells. In vivo, the effect of KP-392
was investigated in a metastatic H460 orthotopic lung cancer model.
Methods: Intraperitoneal KP-392 (5 mg/day per animal) was ad-
ministered both alone and in combination with cisplatin (5 mg/kg
per week for 3 weeks). In group I, all treated animals were followed
until death to assess therapeutic effect on survival. In group II, tumor
growth and metastasis were evaluated by sacrificing one animal
from each treatment when a control animal died.
Results: Both cisplatin and KP-392 significantly enhanced survival
(37.8  3.7 and 34.9  5.2 days) compared with the control (30.2 
3.6 days, p 0.0001 and p 0.0418, respectively), and the survival
benefit from combination treatment was greater than that of either
agent alone (45.8  3.9 days, p  0.0001). Although KP-392 alone
did not impact the incidence of metastasis, in combination with
cisplatin a consistent trend of inhibition was seen for metastases in
the kidney, bone, and the contralateral lung. KP-392 was well
tolerated throughout the study. KP-392 demonstrated increased
tumor necrosis and decreased nuclear phospho–protein kinase/Akt
but did not change the levels of phospho–extracellular signal-
regulated kinase 1/2.
Conclusions: ILK inhibitor does not enhance the toxicity of stan-
dard chemotherapy and may have a beneficial therapeutic effect in
lung cancer.
Key Words: Integrin linked kinase, Integrin linked kinase inhibitor,
KP-392, Lung cancer, Orthotopic lung cancer model.
(J Thorac Oncol. 2006;1: 771–779)
Lung cancer is a disease with high metastatic potential and anoverall 5-year survival rate of less than 15%. More than 65%
of patients present with advanced stage disease and have limited
response to currently available therapies.1,2 Novel cancer thera-
peutics are based on targeting molecular aberrations that are
considered critical for the growth and survival of tumor cells.3
Protein kinases and phosphatases play key roles in cancer cell
biology and may represent one class of such therapeutic targets.4
Integrin-linked kinase (ILK) is a key component of the
integrin-induced signaling cascades that have been demon-
strated to impact tumor cell survival, cell migration, and
angiogenesis.4 ILK is a 59-kilodalton serine/threonine protein
kinase with ankyrin repeats, which interacts with the cyto-
plasmic domains of the 1 and 3 integrin subunits.5 ILK
activity is influenced by both the integrin and growth factor
receptor–initiated signals, which are dependent on phospho-
inositide-3-kinase activity.6 The overexpression of ILK in
epithelial cells results in reduced adhesion when plated on
fibronectin, collagen, or laminin, putatively caused by the down-
regulation of E-cadherin protein expression levels.7 More im-
portantly, ILK overexpression in epithelial cells also induces
transformed phenotypes, including anchorage-independent growth,
cyclin D1 overexpression, suppression of anoikis, increased
invasiveness, and induction of tumorigenicity.7–9
Several small molecules that specifically inhibit ILK
activity in vitro and in vivo were developed and evaluated as
potential novel cancer therapeutics.4 KP-392 was identified in
screening studies to have highly selective activity against
ILK, with its IC50 values in vitro being 100-fold lower than
those of 30 other kinases. KP-392 was therefore considered
suitable for in vivo testing as a highly selective ILK inhibitor.10
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Here, we report the results of in vitro and in vivo studies on the
anticancer efficacy of KP-392 on the NCI-H460 cell line and its
orthotopic lung cancer model in nude rats. This previously
characterized lung cancer model exhibits systemic metastases
simulating clinical human non–small cell lung cancer.11
MATERIALS AND METHODS
Drugs and Solutions
KP-392 was supplied in powder form by Kinetek Phar-
maceuticals, Inc. (Vancouver, BC, Canada) and was stored in
the dark prior to use. For in vitro studies, KP-392 was
dissolved in dimethyl sulfoxide (DMSO). For in vivo injec-
tion, the drug was prepared fresh each day by dissolving 10
mg/ml in a 5% acidic dextrose solution under sterile condi-
tions. A cisplatin solution (1 mg/ml) (Faulding Canada,
Montreal, Quebec, Canada) was obtained from the hospital
pharmacy at the University Health Network. For kinase
assays, cells were lysed in 50 mm of N-(2-hydroxyethyl)-
piperazine-N=-2-ethanesulfonic acid buffer (pH 7.5) contain-
ing NaCl (150 mM), Nonidet P-40 (1%), sodium deoxy-
cholate (0.5%), leupeptin (10 g/ml), phenylmethylsulfonyl
fluoride (1 mM), aprotinin (2.5 l/ml), sodium fluoride (5
mM), and sodium orthovanadate (1 mM).
Cell Line
The NCI-H460 human-lung large cell carcinoma cell
line was obtained from the American Type Culture Collection
(Rockville, MD). The cells were grown in T80 flasks in RPMI
1640 containing 5% fetal bovine serum without antibiotics in a
95% air/5% CO2 atmosphere at 37°C. Cells were subcultured
when they reached approximately 80% confluence.
Animals
Male nude rats (CR:NIH-RNU; Charles River Inc.,
Frederick Cancer Research Facility, Frederick, MD) were
received at 4 weeks of age and acclimated for 1 to 2 weeks
before the start of study protocols. Rats were housed in
sterilized cages and fed autoclaved food and water ad libitum.
The health condition of the animals was assessed daily.
Animals were humanely euthanized by CO2 asphyxiation
when they showed evidence of advanced cachexia or impend-
ing death.
In Vitro Studies of KP-392 on NCI-H460 Cells
Treated and control NCI-H460 cells were 60% conflu-
ent at the time of KP-392 treatment and were 80% confluent
when harvested for biochemical assays. The treatment in-
cluded replacing the culture medium by fresh serum-free
media, then adding KP-392 in DMSO solution to give final
concentrations of 20, 50, or 100 M. Controls were treated
with DMSO solvent alone. The treated and control plates
were incubated at 37°C for 3 hours and then were harvested
as previously described.12 Briefly, lysis buffer was added to
plates and the total cellular lysates were harvested on ice with
a cell scraper, transferred into microcentrifuge tubes, and
vortexed. After 15 minutes of incubation on ice, the lysates
were centrifuged for 10 minutes at 4°C and 14,000 rpm.
Supernatants were used directly or stored at 80°C until
analysis.
Kinase Activity Assay
ILK activity was measured by a kinase assay using its
specific substrate, myelin basic protein, as previously de-
scribed.12 Substrate was omitted in the negative control sample,
and assays were performed in triplicate. Briefly, equivalent
protein concentrations of cell lysates were precleared with non-
specific IgG bound to protein A–sepharose. ILK was immuno-
precipitated from the supernatants by incubating with the ILK
antibody (Upstate Biotechnology, Waltham, MA). After a 20-
min incubation of the immunoprecipitate with substrate and 32P
-ATP at 30°C, the amount of phosphorylated myelin basic
protein substrate was measured using a scintillation counter.
Data represent the mean value  standard deviation of three
experiments. The effect of ILK inhibitors on kinase activity of
ILK was assessed by comparing the counts per minute from
KP-392–treated samples with the DMSO control.12
Western Blot Analysis
Protein extracts from NCI-H460 cells were separated
by electrophoresis in SDS polyacrylamide gel electrophoresis
and transferred onto polyvinylidene fluoride membranes
(Millipore, MA). The membranes were then probed with the
appropriate primary antibodies, and protein was detected
using an horseradish peroxidase–conjugated secondary anti-
body and the electrochemiluminescent detection system. An
antibody specific to the phosphorylated protein kinase B
(PKB), phosphoserine 473, was used as a surrogate indicator
of ILK activity13 in Western blot analysis (Cell Signaling
Technology, Waltham, MA). As a control, the blots were also
probed with antibody against the unphosphorylated PKB/Akt
(Cell Signaling Technology). Densitometric and image analy-
sis of exposed Biomax-MR films (Kodak) were used to deter-
mine the impact of inhibitor on phospho-PKB/Akt levels.
Immunocytochemistry
The NCI-H460 cells were seeded onto eight-chamber
slides at a density of 104 cells per well and treated with 25
M of KP-392 when the cells reached 60 to 80% confluence.
Cells were fixed in ice-cold methanol at various times be-
tween 2 and 24 hours after the initiation of treatment and then
incubated overnight at 4°C with the primary antibodies. To
evaluate ILK, phospho-PKB/Akt and phosphorylated glyco-
gen synthase kinase 3 beta (GSK3-) levels, antibodies to
ILK, phospho-PKB/Akt at Ser-473, and phospho–GSK3-
were used at a concentration of 2 g/ml. This was followed
by incubation with the secondary antibody, biotinylated rab-
bit–IgG at a concentration of 7 g/ml. Streptavidin-peroxi-
dase was used as a detection system. 3-3= diaminobenzidine
tetrahydrochloride was used as a chromogen, and the cells
were counterstained with hematoxylin. Microphotographs
were generated using a Nikon Eclipse TE 200 microscope
and Nikon Cool Pix 950 digital camera.
Construction of H460 Orthotopic Lung Cancer
Model for In Vivo Studies
Prior to the animal experiments, an institutional animal
care approval was obtained from University Health Network/
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Ontario Cancer Institute, University of Toronto. All manip-
ulations were done under sterile conditions in a laminar flow
hood. The H460 orthotopic lung cancer model was previously
described in detail.11 Briefly, NCI-H460 cells were implanted
endobronchially into the lungs of preirradiated nude rats via
a small tracheotomy incision. Three weeks after tumor im-
plantation, a lung tumor mass was harvested, and fresh tumor
tissue from its periphery was mechanically cut into 0.5- to
1.0-mm diameter pieces in a sterile Petri dish. Tumor tissue
fragments from multiple donor animals were mixed thor-
oughly and then divided as precisely as possible into equal
50-mg portions for secondary orthotopic endobronchial im-
plantation into newly obtained preirradiated animals. In each
experiment, the animals were randomly divided into three
treatment arms and one control arm after tumor implantation.
The animals were treated prophylactically with Augmentin
(Beecham Labs, Bristol, TN) at 0.35 mg/ml in water for 1
week after implantation.
In Vivo Treatment with KP-392 and Cisplatin
Both KP-392 (5 mg daily per animal) and cisplatin (5
mg/kg weekly for 3 weeks) were administered by intraperi-
toneal injection using 25-gauge needles. The dosage of KP-
392 was based on initial in vivo pharmacokinetic and phar-
macodynamic data obtained from healthy rats. It is the
optimal amount of compound in a stable solution that gave
detectable blood levels (using high-pressure liquid chroma-
tography) in normal rats over 24 hours. This dose was
sufficient to inhibit ILK activity in vitro using biochemical
kinase assays and reduced cell invasion and migration using
biological assays.4,6,10 Treatment with KP-392 and cisplatin
commenced 7 and 14 days postimplantation, respectively.
The study protocol consisted of four arms: a vehicle control
arm (5% acidic dextrose solution) and three treatment arms
(KP-392 alone, cisplatin alone, and a combination of the two
agents). Two distinct end points were evaluated: 1) length of
survival (group I) and 2) growth and metastatic spread of the
primary lung tumor (group II). In group I (n  12 per
treatment arm), the maximal length of survival was measured
by following all treated animals until death. In group II (n 
8 per treatment arm), a single animal from each treatment arm
was sacrificed when a control animal died. A direct compar-
ison of each treatment arm at the same time point is then
possible for tumor-associated end points, including primary
tumor weight, mediastinal lymph node weight, and metasta-
ses. Animals that died less than 10 days following implanta-
tion were considered postanesthetic or surgical complications
and were eliminated from the final analysis. The physical
performance of each animal was carefully recorded using
standardized scoring criteria that assessed the general well-
being of the animal. The three parameters for assessment
included skin coat condition, animal mobility/activity level,
and respiratory status. They were scored as 0 (normal), 1
(mild condition), 2 (moderate condition), 3 (severe condi-
tion), or 4 (critical condition).
Assessment of Metastases
Careful necropsies were performed after death of the
animals. Internal organs, including lung, kidney, brain, chest
wall or bone, and lymph nodes were removed, fixed in 10%
buffered formalin, and embedded in paraffin. All tissues were
serially sectioned and stained with hematoxylin and eosin for
microscopic examination. Any macroscopic or microscopic
tumor deposit discovered (other than the primary tumor) was
considered a metastasis. Organs or tissue were counted as
either positive or negative for metastasis. No assessments of
the number or extent of metastasis were made, except for the
weight of the mediastinal lymph node, which invariably was
totally replaced with tumor.
Blood Collection and Serum Chemistry
Determinations
To assess toxicity, the kidney and liver functions of
each animal were evaluated by blood biochemistry. Approx-
imately 3 ml of blood was collected from anesthetized rats by
cardiac puncture before the rats were sacrificed in a protein
sequence tag gel and lithium heparin green-top vacutainer
(Becton-Dickerson, Franklin Lakes, NJ) and placed on ice.
After centrifugation at 2500 g for 15 min, the plasma was
collected and was sent to the Toronto Medical Laboratory
Biochemistry Department for analyses of creatinine, blood
urea nitrogen, aspartate aminotransferase, alanine amino-
transferase, and alkaline phosphatase.
Immunostaining of Tumor Tissue Array
Excised primary lung tumors from control and KP-
392–treated animals from group II were sliced into 5-mm or
less thickness and fixed overnight in 10% buffered formalin,
then processed for paraffin embedding. The hematoxylin and
eosin (H & E) stained slides were evaluated for percent area
of necrosis. Tissue cores from viable tumor areas as identified
by the H & E slides were selected to construct a tissue
microarray using the manual tissue arrayer (Beecher Instru-
ments, Sun Prairie, WI). Tissue cores of 0.6 mm (six per
tumor) were taken from each tumor block of control and
KP-392–treated animals. Four-micron serial sections of the
tissue array block were used for immunohistochemistry
(IHC). The antibodies against ILK (Upstate, Charlottesville,
Virginia), phospho–extracellular signal-regulated kinase
(ERK; Thr202/Thr204), and phospho-PKB (Ser473), (Cell
Signaling Technologies, Beverly, MA) were used at 1:100,
1:200, and 1:400 dilutions, respectively. Preprocessing in-
cluded an antigen-retrieval procedure of placing slides in 10
mM citrate buffer, pH 6.0, with microwave heating at 120°C
(T/T Mega microwave oven, Milestone, Sorisole, Italy) for 10
min. Incubation with the primary antibody was for 16 hours at
room temperature, and signal detection was performed using an
ultrastreptadvidin horseradish peroxidase detection system (Sig-
net Laboratories, Dedham, MA) with the NovaRed substrate kit
(Vector Laboratories, Burlingame, CA).
Image Analysis
Sections were visualized using a transmitted light mi-
croscope (Zeiss Axioskop) with a 10, NA 0.25 objective
lens. Images were acquired using MicroComputer Image
Device, version Elite 7.0, software (Imaging Research Inc.,
St. Catharines, ON, Canada) linked to a three-color CCD
Sony DXC 970 MD camera mounted on the microscope.
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Using composite images from tiled fields of H & E stained
whole-tumor sections (5 mm in diameter), regions of ne-
crosis were selected by visual inspection, and percent of
necrotic area was calculated using software modules in the
Interactive Data Language (IDL 6.0, Research Systems, Inc.,
Boulder, CO) written by Andrew Morrison.14 To assess the
expression levels of each protein marker, a semiquantitative
method as described by Hirsch et al.15 was used to generate
a composite score for each core on tissue microarray slide.
The percentage of positively stained viable tumor cells per
core (0–100%) was multiplied by the dominant intensity of
the staining pattern (1 negative to 4 intense), thus giving
an overall score that ranged from 0 to 400. All evaluations
were performed without knowledge of the identity or origin
of these tissue cores.
Statistical Analysis
Survival and the physical performance of animals were
studied using the group I animals. The percentage of animals
surviving at each time point was calculated using the Kaplan–
Meier method, and the difference between treatment arms
was tested using the log-rank test. Data were summarized by
plotting Kaplan–Meier estimates. The same techniques were
used to calculate the percentage of animals with grade 3
physical performance conditions at each time point. Treat-
ment arms were compared using the log-rank test. To sum-
marize the results, the percentage of animals at grade 3 for
each condition by 30 days and their 95% confidence intervals
were plotted. We also calculated the mean and standard
deviation of the time to death. All rats were dead at the end
of the study, and thus the mean time to death is not biased.
Tumor growth and metastases were assessed using the group
II animals. A McNemar test was used to compare the inci-
dence of metastasis between each treatment arm and the
control arm. Animal body weight, tumor weight, lymph node
weight, tumor/body weight ratio, and blood biochemistry data
were compared between treatment arms and the control arm
using the signed rank test. The data was summarized as the
mean  standard deviation. A one-tailed, nonparametric
Mann–Whitney test was applied to the microscopy analysis.
Tests that produced p values equal to or less than 0.05 were
considered significant.
RESULTS
Effects of KP-392 on NCI-H460 Cells In Vitro
NCI-H460 cells in culture demonstrated constitutive
ILK kinase activity, and the activity levels were optimal
during log phase or subconfluent growth. Treatment of the
NCI-H460 cells with KP-392 led to a significant inhibition
of the ILK activity as determined by the biochemical
kinase assay (Fig. 1A). A 3-hour treatment of these cells
with KP-392 did not change the levels of ILK, PKB, and
GSK3- proteins (data not shown), but it showed a dose-
dependent reduction in the levels of phosphoSer-473-PKB
(Fig. 1B). Optimal inhibition occurred at 100 M KP-392
and after a minimum treatment of 3 hours. Complete
inhibition of PKB/Akt phosphorylation at serine 473 was
detected at higher concentrations of KP-392, but the study
was limited by a DMSO solvent effect. The NCI-H460
cells grown in slide chambers also demonstrated marked
FIGURE 1. (A) ILK activity was measured in H460 cells after 3-hour incubation with KP-392 or solvent (control). Background
levels included reagents without cells. All treatments were performed in triplicate; error bars represent SD of each sample
group. KP-392 significantly inhibited the ILK activity derived from the H460 cells in this biochemical assay. (B) Detection of
decreasing amounts of phospho-PKB/AKT by Western analysis resulted from a dose-dependent effect of KP-392 inhibition on
ILK. Cell lysates were harvested after 3 hours of drug incubation. There was a significant decrease in phospho-PKB/AKT
(SER473) at 100 M drug. (C, D) Immunocytochemical analysis of DMSO control (C) and KP-392–treated (D) H460 cells.
Phospho-PKB (Ser-473) level was significantly reduced following 3 hours of treatment with KP-392.
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suppression of phospho-PKB/Akt immunostaining after
4-hour treatment with 25 M KP-392 (Fig. 1, C and D). A
similar result was obtained with an immunoblot for phos-
phoSer-9-GSK3- (data not shown). These results con-
firmed that the NCI-H460 lung carcinoma cell line was an
appropriate target for kinase inhibition by ILK-specific
small molecule inhibitors in an in vivo model.
Effect of KP-392 on Survival in the NCI-H460
Orthotopic Lung Cancer Model (Group 1)
The fidelity of the NCI-H460 orthotopic lung cancer
model was demonstrated in this study.11 Vehicle-treated con-
trol animals maintained similar life span and metastatic pat-
tern compared with the originally described model system.
All control animals showed a mean survival time of 30.2 
3.6 days following tumor implantation, and all succumbed to
metastatic disease. The cisplatin alone was 37.8  3.7 days,
and mean survival time for animals treated with KP-392
alone was 34.9  5.2 days. Thus, both cisplatin and KP-392
significantly prolonged survival in tumor-bearing animals
(p  0.0001 and p  0.0418, respectively). The combined
cisplatin and KP-392 treatment further increased the length of
survival compared with the control arm (45.8  3.9 versus
30.2  3.6 days, p  0.0001) and compared with both
single-agent treatment arms (p  0.0002 versus KP-392; p 
0.0006 versus cisplatin) (Fig. 2).
Effect of KP-392 on Primary Tumor Growth
and Metastasis (Group II)
An equal number of animals (n  8) from the control
arm and each of the three treatment arms were included in
this investigation. As a control animal died, one animal from
each treatment arm was sacrificed so that the end points
would be temporally consistent. Primary tumor weight and
the weight of the anterior mediastinal lymph node group
(always fully replaced with metastatic tumor) were measured
to evaluate tumor burden. Tumor/body weight ratio was an
additional parameter to assess primary tumor growth cor-
rected for body size. Table 1 shows that cisplatin treatment
alone exhibited an inhibitory effect on the primary tumor
growth by reducing the tumor weight. This effect approached
statistical significance (p  0.0547). Furthermore, cisplatin
FIGURE 2. Kaplan–Meier survival curves of vehicle-treated
control animals and three treatment arms, including cisplatin
alone, KP-392 alone, and cisplatin  KP-392. Both KP-392
alone and cisplatin  KP-392 significantly prolonged survival
compared with vehicle controls (p  0.0418 and p  0.0001,
respectively). The combined cisplatin  KP-392 regimen
showed better survival than cisplatin treatment alone (p 
0.0006).
TABLE 1. Effect of treatments on primary/lymph node tumor weight (group II animal studies;
n  8 for each group)
Drug Body weight (g) Tumor weight (g) LN weight (g) Tumor/body weight ratio
Control 130.6  17.4 8.53  2.47 0.34  0.2 0.07  0.02
Cisplatin 126.3  9.16 4.68  2.28 0.10  0.11* 0.04  0.02
KP-392 160.6  29.2* 6.71  2.87 0.27  0.19 0.04  0.03
Cisplatin  KP-392 134.4  13.2 4.17  2.18* 0.14  0.11** 0.03  0.01*
LN, mediastinal lymph node.
*p  0.05; **p  0.01 compared with control group by signed rank test.
TABLE 2. Effect of treatment on metastases
Treatment Mediastinal LN Kidney Bone Brain Gum Left lung
Control 8/8 (100%) 5/8 (62.5%) 8/8 (100%) 6/8 (75%) 5/8 (62.5%) 8/8 (100%)
Cisplatin 8/8 (100%) 1/8 (12.5%) 5/8 (62.5%) 2/8 (25%) 3/8 (37.5%) 4/8 (50%)
KP-392 8/8 (100%) 3/8 (7.5%) 6/8 (75%) 5/8 (62.5%) 5/8 (62.5%) 5/8 (62.5%)
Cisplatin  KP-392 6/8 (75%) 0/8 (0%)* 3/8 (37.5%)* 2/8 (25%) 2/8 (25%) 3/8 (37.5%)*
LN, lymph node.
*p  0.0625, marginal close to 0.05 vs. control by McNemar test.
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significantly decreased mediastinal lymph node tumor burden
(p  0.0391). Although KP-392 alone showed no direct
effect on either primary tumor or lymph node tumor growth,
the combination of cisplatin and KP-392 significantly de-
creased both (p  0.0391 and 0.0078, respectively). This
combination therapy also significantly reduced the tumor/
body weight ratio compared with the control group (p 
0.0156), suggesting a benefit of this regimen even when
corrected for animal body weight.
The incidence of metastasis was carefully documented
macroscopically and microscopically. Control animals main-
tained very high metastatic rates in the mediastinal lymph node
(100%), kidney (62.5%), bone (100%), left lung (100%), brain
(75%), and gingival soft tissue (62.5%). Although KP-392 and
cisplatin alone showed no decrease in the metastatic rates at
various sites, the combination of cisplatin and KP-392 treatment
showed a consistent trend toward inhibition of metastases to the
kidney, bone, and left lung (p  0.0625 versus control by
McNemar test). No additive inhibitory effect on tumor metas-
tasis was seen with the combination regimen compared with
cisplatin treatment alone (Table 2).
Analysis of H & E and Immunostaining
Although not statistically significant by Mann–Whitney
test (p  0.11), tumors of animals treated with KP-392
showed a median of 58% necrosis compared with 41.5%
necrosis in tumors from control animals (Fig. 3). To assess
the effect of drug treatments on signaling protein levels,
tissue arrays composed of tumors from each treatment arm
were constructed (Fig. 4A). Evaluation was performed on
cores that were at least 75% intact. Tumor and stromal cells
of control and treated animals showed moderate to intense
IHC staining with ILK antibody (Fig. 4B). Animals treated
with KP-392 showed a significant decrease in nuclear phos-
pho-PKB/Akt staining (p  0.01) compared with control
animals (Fig. 5), with no differences observed for total
cellular phospho-PKB/Akt. There was no significant change
in the levels of phospho-ERK (Fig. 5) in treated or control
tumors.
FIGURE 3. Image analysis was performed on H & E stained
whole-tumor sections for the quantification of percent area
of necrosis. Whiskers plot the minimum and maximum value,
and a box plots the first quantile, median, and third quan-
tile. The median for KP-392–treated animals is higher than
vehicle-treated controls but not significant (p  0.11).
FIGURE 4. A representative ILK-
labeled tissue array image (A), cap-
tured using a Sprint Scan 35 Plus
(Polaroid, Waltham, MA), shows
groups of six cores per tumor spec-
imen. An image of a typical core
from an array stained with ILK
shows moderate to intense expres-
sion in tumor and stromal cells (B),
20 objective lens.
FIGURE 5. An IHC score was ap-
plied to evaluate phospho–protein
kinase B (Ser473) and phospho–
extracellular signal-regulated kinase
(Thr202/Thr204) in tissue arrays (A).
A box plots the first quantile, median,
and third quantile, and whiskers plot
the minimum and maximum value.
The median value of nuclear phos-
pho–protein kinase B staining in KP-
392–treated animals is significantly
less than control, p  0.01. Represen-
tative images from the control tissue
array (B and C) specimens showing
intense and weak phospho–protein
kinase B stain, respectively (40 ob-
jective lens, ScanScope CS, Aperio
Technologies, Vista, CA).
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Biochemistry and Physical Performance Profile
KP-392, both alone and in combination with cisplatin,
was well tolerated as assessed by body weights, blood bio-
chemistries, and physical performance scores. The blood
biochemistry evaluations revealed that KP-392 alone or in
combination with cisplatin did not compromise kidney and
liver function compared with vehicle-treated control animals.
Moderate elevation of urea and aspartate aminotransferase
levels were noted in some control animals, which is consis-
tent with advanced metastatic disease. The analyses of phys-
ical performance scoring, including skin coat condition, re-
spiratory movement, and mobility (activity level) at day 30
are shown in (Figure 6A, B, and C). The data suggest that
overall physical condition of the animals treated by KP-392
alone, or in combination with cisplatin, were better than
control animals and those treated with cisplatin alone.
DISCUSSION
We have demonstrated that treatment with the novel
small-molecule ILK inhibitor, KP-392, prolongs survival in
the H460 metastatic orthotopic lung cancer model. Survival
was further enhanced when KP-392 was combined with
cisplatin. This combination also showed reduction in the
weight of primary lung tumors and regional lymph node
tumors and a decrease in the incidence of systemic metasta-
sis. Only one dosage of KP-392 was used in this study, and
a more significant response may be realized with higher
dosages. Future studies should address this issue.
Because the H460 orthotopic lung cancer model repro-
ducibly generates extensive systemic metastasis and eventual
cancer-related mortality, survival is a feasible study end
point. The model is also useful in differentiating both primary
tumor inhibition and the antimetastatic effect of novel agents.
Novel drugs that selectively interfere with an important
pathway controlling cancer cell survival, proliferation, and/or
metastasis have recently generated enormous clinical inter-
est.16 This is the first study to show that a selective ILK inhibitor
significantly decreases lung cancer cell growth in vitro and in
vivo. Integrins regulate cell adhesion, migration, and signal-
ing processes involved in proliferation and survival.17 ILK is
a key enzyme in integrin and growth factor signaling path-
ways. ILK induces the phosphorylation and inhibition of
GSK3- and the subsequent activation of AP-1 and -cate-
nin/LEF-1 transcription factors, which results in the expres-
sion of mesenchymal-related genes.6 ILK overexpression also
results in the suppression of apoptosis, putatively through the
phosphorylation and activation of antiapoptotic PKB/Akt.18
Gain- and loss-of-function studies have shown that overex-
pression and/or constitutive activation of ILK result in onco-
genic transformation and progression to invasive and meta-
static phenotypes.19 Pharmacological inhibition of ILK
results in inhibition of cell proliferation and PKB/Akt phos-
phorylation, inducing cell cycle arrest and apoptosis.4
Overexpression of ILK has been documented in a wide
variety of human malignancies including colon cancer, breast
cancer, prostate cancer, and ovarian cancer.20–22 Studies have
also shown that increased ILK expression is associated with
tumor invasion and progression5,23,24 and is inversely corre-
lated with patient survival in melanoma.23 Clinical monitor-
ing of immunoreactive ILK expression in the serum and
peritoneal fluid was performed in ovarian cancer patients with
or without chemotherapy.20 In that study, ILK expression was
FIGURE 6. Physical health of ani-
mals evaluated by skin coat condi-
tion, respiratory movement, and
mobility at day 30 following tumor
implantation. They were scored as
0 (normal), 1 (mild condition), 2
(moderate condition), 3 (severe
condition), or 4 (critical condition).
No animal reached condition 4 in
accordance with the humane end
point established by animal care
regulations. The data are presented
as mean  SD. (A) Percentage of
animals reaching grade 3 for skin
coat condition. (B) Percentage of
animals reaching grade 3 for respi-
ratory distress. (C) Percentage of
animals reaching grade 3 for mo-
bility/activity.
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six- to ninefold higher in the serum of patients with ovarian
cancer than in healthy volunteers and was reduced to normal
levels after six cycles of paclitaxel and carboplatin chemo-
therapy. The results suggest a potential role of ILK as a
biomarker for early detection and for monitoring the clinical
condition of patients after treatment.
In the current study, treatment with either KP-392 or
cisplatin alone resulted in a modest prolongation of survival.
However, when both agents were given in combination,
significantly greater suppression of metastasis and longer
survival were noted. This is in keeping with clinical experi-
ence showing that novel targeted therapeutic agents are usu-
ally more effective when administered in combination with
standard cytotoxic agents or other compounds acting on
parallel signaling pathways.25 Modulation of PKB/Akt activ-
ity alters sensitivity of non–small cell lung cancer cells to
chemotherapy.26 In particular, ectopic expression of AktI
results in enhanced chemoresistance of H460 non–small cell
lung cancer cells toward a panel of chemotherapeutic agents
including cisplatin, possibly by interfering with and delaying
the onset of various apoptotic pathways.27 The antimetastatic
effect of the combination therapy is unclear, although previ-
ous studies have revealed that integrin signaling deregulates
MMP-2, MMP-9, and MT1-MMP expression,28,29,30 which
putatively play important roles in angiogenesis and the met-
astatic spread of tumor cells.31–34 We have previously re-
ported that orthotopic H460 tumors express MMP-2, MT1-
MMP (MMP-14), and TIMP-2.35 The mechanism of the
antimetastatic effect of KP-392 remains to be determined, as
does the effect of KP-392 on the expression of matrix
metalloproteinases and tissue inhibitors of metalloproteinases
in H460 tumor cells.
Tan et al. recently showed that ILK stimulates the expres-
sion of vascular endothelial growth factor in human prostate
cancer cells. Inhibition of ILK expression or activity resulted in
a decrease in vascular endothelial growth factor–mediated en-
dothelial cell migration, capillary formation in vitro, and angio-
genesis in vivo. Inhibition of ILK activity also inhibited prostate
tumor angiogenesis and suppressed tumor growth.36 In our
study, the trend toward more tumor necrosis in KP-392–treated
tumors than in nontreated vehicle control tumors (Fig. 3) may
well reflect an antiangiogenic effect of the ILK inhibitor. It
further supports a hypothesis that ILK may be a critical thera-
peutic target for antiangiogenesis.
Observation of the three physical performance indicators—
skin coat condition, respiratory movement and activity—
demonstrated that KP-392 treatment alone or in combination
with cisplatin gave better scores on a daily basis than the control
animals or those treated with cisplatin alone. More likely, these
scores reflect a slower progression of tumor growth and metas-
tasis; however, it is possible that the increased tumor necrosis
seen in the KP-392–treated animals may decrease tumor-
induced cachexia, resulting in improved performance.
The examination of immunostaining in viable tumor
areas showed ILK expression in tumor cells. Drug-treated
animals showed no significant changes in phospho-ERK or
total phospho-PKB/Akt; however, KP-392 treatment demon-
strated reduced nuclear phospho-PKB/Akt levels in tumor
cells. This suggests that ILK has an impact on the oncogenic
phosphoinositide-3-kinase–PKB signaling pathway. Consti-
tutive activation of PKB/Akt was expressed predominantly in
the nucleus.37 A recent study showed that phosphorylated
PKB/Akt is frequently activated in non–small cell lung can-
cer cells. Immuonstochemistry revealed that PKB/Akt was
detected either in the cytoplasm or nucleus of human non–
small cell lung cancer cells.38 Overall, the findings reported
here provide strong evidence that a selective ILK inhibitor is
a promising novel therapeutic agent in the treatment of lung
cancer.
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